Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
10: 586–588 © 1995 Lippincott–Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndrome
Volume 10, 1995

Author Index

Ahmad A, 115
Altice FL, 441
Ammann AJ, 150
Anthony DL, 104
Anzala A, 457
Arkin S, 471

Baba M, 393
Bakker PJM, 61
Battjes RJ, 90
Beijnen J, 163
Bergeron D, 1
Berggren RE, 489
Bertazzoni U, 198
Berti E, 295
Biberfeld P, 295
Biglione M, 198
Biron F, 36
Birx DL, 13
Blank A, 205
Blank M, 205
Blattner W, 192
Bonavida B, 331
Brattegaard K, 358
Broadhead RS, 104
Brouwer PA, 61
Brown LS Jr, 90
Brundage JF, 177
Brunell PA, 540
Bruunsgaard H, 107
Bult A, 163
Bulterys M, 186
Burger D, 163
Burke DS, 13, 177
Busch MP, 522
Bush TJ, 374
Bwayo JJ, 457

Caetano R, 554
Cameron W, 54
Canaris AD, 462
Cantalamessa A, 462
Capitani S, 306
Carlson JR, 381
Caruso A, 462
Casoli C, 198
Castillo LC, 192
Castro KG, 374
Cattaneo E, 198
Cavalcanti AS, 486
Cedeño V, 192
Celentano DD, 97, 477
Chao A, 186
Charron K, 386
Checko PJ, 562
Checroune F, 1
Chen S, 139
Chesney MA, 341
Chirianni A, 450
Chopra P, 139
Choudhri S, 457
Chu P, 441
Chu SY, 374, 562
Cimarelli A, 198
Clements ML, 386
Clifford DB, 169
Cohen EA, 1
Collier AC, 150
Conrad AJ, 425
Conri C, 392
Constans J, 392
Conti L, 562
Cooke M, 341
Coombs RW, 150
Cordeiro MT, 486
Corey L, 150
Coulibaly D, 358
Coulibaly I-M, 358
Courville TM, 540

da Silva GA, 486
Daar E, 540
Dantas MC de S, 486
Davidson AJ, 562
Dayton AI, 317
Dayton ET, 317
De Clercq E, 8
De Cock KM, 358
de Panfilis G, 462
De Rosa V, 408
de Souza AI, 486
Deal CD, 13
D'Egidio M, 450
Detels R, 331
Diallo MO, 358
Diaz T, 562
Djomand G, 358
Doherty MC, 97
Donfield SM, 471
Doyle B, 562
Duclos CA, 198
Duke RC, 489
Duliege AM, 150
Dushimimana A, 186

Easterbrook MD, 496
Eisenberg M, 436
Eiumtrakul S, 477
Ekpini E, 358
Embree J, 457
Emini EA, 139
Endert E, 531
Epand RM, 496
Evatt B, 471

Fabry JA, 27
Fajans P, 569
Fang FC, 489
Fann SA, 562
Farzadegan H, 186
Fehrs LJ, 82
Fichtenbaum CJ, 169
Figueira F de S, 486
Fischl M, 549
Fleming PL, 374
Fleury H, 392
Folghera S, 462
Fong I, 48
Ford K, 569
Frederick M, 562
Frerichs RR, 484
Fresard A, 36
Friedman HM, 324
Frissen J, 163
Furlini G, 306, 408

Galai N, 477
Gallicano K, 54
Gallo RC, 295
Garber G, 54
Gargosky SE, 129
Garotta G, 462
Gendelman R, 295
Gessain A, 198
Ghinelli F, 450
Ghys P, 358
Gibellini D, 306
Gibson J, 150
Giorgi JV, 331
Gleghorn AA, 97
Gnaore E, 358
Godfried MH, 531
Gomez AM, 496
Göttlinger HG, 1
Gracia F, 192
Graham NMH, 366
Grange J, 36
Graziani AL, 324
Greenberg AE, 358
Groseclose SL, 73, 82
Grund J-PC, 104
Guerra L, 450

Hahn BH, 139
Hamedi-Sangsari F, 36
Hansen J-ES, 400
Hanson D, 374
Harrison K, 386
Hashida S, 41
Hashimoto K-i, 393
Hashinaka K, 41
Hausner MA, 331
He YD, 366
Hebeda KM, 61
Heckathorn DD, 104
Heimer R, 175
Heinkelein M, 417
Hendrickx AG, 129
Heneine W, 192
Henrichs J, 163
Hermann P, 562
Herr M, 562
Himmelgreen D, 104
Hines AM, 554
Hinton DR, 511
Hirji K, 331

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
10: 586–588 © 1995 Lippincott–Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndrome
Volume 10, 1995

Author Index

Ahmad A, 115
Altice FL, 441
Ammann AJ, 150
Anthony DL, 104
Anzala A, 457
Arkin S, 471

Baba M, 393
Bakker PJM, 61
Battjes RJ, 90
Beijnen J, 163
Bergeron D, 1
Berggren RE, 489
Bertazzoni U, 198
Berti E, 295
Biberfeld P, 295
Biglione M, 198
Biron F, 36
Birx DL, 13
Blank A, 205
Blank M, 205
Blattner W, 192
Bonavida B, 331
Brattegaard K, 358
Broadhead RS, 104
Brouwer PA, 61
Brown LS Jr, 90
Brundage JF, 177
Brunell PA, 540
Bruunsgaard H, 107
Bult A, 163
Bulterys M, 186
Burger D, 163
Burke DS, 13, 177
Busch MP, 522
Bush TJ, 374
Bwayo JJ, 457

Caetano R, 554
Cameron W, 54
Canaris AD, 462
Cantalamessa A, 462
Capitani S, 306
Carlson JR, 381
Caruso A, 462
Casoli C, 198
Castillo LC, 192
Castro KG, 374
Cattaneo E, 198
Cavalcanti AS, 486
Cedeño V, 192
Celentano DD, 97, 477
Chao A, 186
Charron K, 386
Checko PJ, 562
Checroune F, 1
Chen S, 139
Chesney MA, 341
Chirianni A, 450
Chopra P, 139
Choudhri S, 457
Chu P, 441
Chu SY, 374, 562
Cimarelli A, 198
Clements ML, 386
Clifford DB, 169
Cohen EA, 1
Collier AC, 150
Conrad AJ, 425
Conri C, 392
Constans J, 392
Conti L, 562
Cooke M, 341
Coombs RW, 150
Cordeiro MT, 486
Corey L, 150
Coulibaly D, 358
Coulibaly I-M, 358
Courville TM, 540

da Silva GA, 486
Daar E, 540
Dantas MC de S, 486
Davidson AJ, 562
Dayton AI, 317
Dayton ET, 317
De Clercq E, 8
De Cock KM, 358
de Panfilis G, 462
De Rosa V, 408
de Souza AI, 486
Deal CD, 13
D'Egidio M, 450
Detels R, 331
Diallo MO, 358
Diaz T, 562
Djomand G, 358
Doherty MC, 97
Donfield SM, 471
Doyle B, 562
Duclos CA, 198
Duke RC, 489
Duliege AM, 150
Dushimimana A, 186

Easterbrook MD, 496
Eisenberg M, 436
Eiumtrakul S, 477
Ekpini E, 358
Embree J, 457
Emini EA, 139
Endert E, 531
Epand RM, 496
Evatt B, 471

Fabry JA, 27
Fajans P, 569
Fang FC, 489
Fann SA, 562
Farzadegan H, 186
Fehrs LJ, 82
Fichtenbaum CJ, 169
Figueira F de S, 486
Fischl M, 549
Fleming PL, 374
Fleury H, 392
Folghera S, 462
Fong I, 48
Ford K, 569
Frederick M, 562
Frerichs RR, 484
Fresard A, 36
Friedman HM, 324
Frissen J, 163
Furlini G, 306, 408

Galai N, 477
Gallicano K, 54
Gallo RC, 295
Garber G, 54
Gargosky SE, 129
Garotta G, 462
Gendelman R, 295
Gessain A, 198
Ghinelli F, 450
Ghys P, 358
Gibellini D, 306
Gibson J, 150
Giorgi JV, 331
Gleghorn AA, 97
Gnaore E, 358
Godfried MH, 531
Gomez AM, 496
Göttlinger HG, 1
Gracia F, 192
Graham NMH, 366
Grange J, 36
Graziani AL, 324
Greenberg AE, 358
Groseclose SL, 73, 82
Grund J-PC, 104
Guerra L, 450

Hahn BH, 139
Hamedi-Sangsari F, 36
Hansen J-ES, 400
Hanson D, 374
Harrison K, 386
Hashida S, 41
Hashimoto K-i, 393
Hashinaka K, 41
Hausner MA, 331
He YD, 366
Hebeda KM, 61
Heckathorn DD, 104
Heimer R, 175
Heinkelein M, 417
Hendrickx AG, 129
Heneine W, 192
Henrichs J, 163
Hermann P, 562
Herr M, 562
Himmelgreen D, 104
Hines AM, 554
Hinton DR, 511
Hirji K, 331

Hirota K, 41
Hirsch M, 549
Hirschkorn D, 522
Hodinka RL, 324
Hofman FM, 511
Holodniy M, 150
Hoover DA, 366
Hoover DR, 485
Hu DJ, 374
Hu P-F, 331
Huizing MT, 61
Hulsebosch HJ, 61
Hultin LE, 331
Hultin P, 331

Iacobelli S, 450
Ishikawa E, 41
Ishikawa S, 41
Israele V, 540
Iversen J, 400
Izu AE, 150

Jablonowski H, 157
Jason J, 471
Jassoy C, 417
Jewett A, 331
Johnson D, 522
Jones JL, 374
Jones K, 386
Jones TS, 73, 82, 97

Kaaya EE, 295
Kadio A, 358
Kaplan EH, 175
Kaplan JE, 192, 374
Kappes JC, 139
Karim A, 549
Kassler WJ, 73, 82
Katzenstein D, 150
Kersey KS, 13
Kessler H, 549
Kimani J, 457
Kingsley L, 366
Koks K, 163
Konings DAM, 317
Kral AH, 381
Kroon F, 163
Kuntolbutra S, 477
Kurawige J-B, 186

La Placa M, 306, 408
Lange JMA, 531
Larreategui M, 192
Lee L, 207
Leng B, 392
Lester P, 341
Levine PH, 192
Levy MH, 496
Lewis D, 436
Licenziati S, 462
Lieberman J, 27
Lifson AR, 381
Lifson JD, 139
Loeb M, 48
Lolli S, 408
Lonati MA, 462
Loomis LD, 13
Looney D, 489
Lourido MA, 205
Lubeck DP, 350
Lucht F, 36

MacGregor RR, 324
MacRae D Jr, 207
Malley S, 36
Marchisio M, 306
Marthas ML, 129
Matsuno S, 350
Mauclère P, 198
Mauss S, 157
Mazzi M, 206
Mazzoni M, 306
McChesney MB, 129
McFarland R, 139
McLellan AT, 577
McNeil JG, 177
Meenhorst P, 163
Menezes J, 115
Merigan T, 150, 549
Metzger DS, 577
Meyers K, 577
Milani D, 306
Miller CJ, 129
Mokotoff E, 562
Montzka DP, 324
Mordenti J, 150
Moses S, 457
Mulder JW, 163, 531
Murphy J, 471
Mwatha A, 457

Nagelkerke NJD, 457
Nagra RM, 425
Nagy-Agren SE, 441
Napel C ten, 163
Natoli C, 450
Navaline H, 577
Nawrocki P, 186
Ndinya Achola JO, 457
Nelson G, 391
Nelson KE, 477
Neyts J, 8
Ngugi EN, 457
Nichols CW, 324
Nielsen C, 400
Nielsen JO, 400
Nugier F, 36
Nys N, 391

Odehouri K, 358
O'Dell MW, 350
O'Driscoll P, 350
Oishi JS, 366
Oka S, 41
Oliveira MJC, 486
Oosting JH, 61
Ordonez C, 295
Ortona L, 450
Otysula M, 129

Pakola SJ, 324
Pakuts A, 54
Palenicek JP, 366
Palumbo P, 436
Park I-W, 506
Parravicini C, 295
Partridge JC, 341
Peacock CD, 120
Pedersen BK, 107
Pedersen C, 107
Pellegrin I, 392
Pellegrin J-L, 392
Pennypacker C, 391
Perales M-A, 27
Perelson AS, 391
Pessoa VP, 486
Peyramond D, 36
Phillips J, 48
Piatak M Jr, 139
Piazza M, 450
Pickens RW, 90
Plummer FA, 457
Pottage J, 549
Powderly WG, 169, 549
Powell DM, 317
Price P, 120

Rachlis A, 48
Ramazzotti E, 408
Re MC, 306, 408
Redfield RR, 13
Reiss P, 61
Renzullo PO, 177
Rezza G, 206
Richman D, 549
Roberts B, 192
Roderigo G, 408
Rolfs RT, 73
Rosenthal KL, 496
Russell JJ, 425

Saag MS, 139
Saah AJ, 186, 366
Sahai J, 54
Saitoh A, 41
Salit I, 48
Saltzberg AM, 207
Samuel MC, 562
Sandhu M, 540
Sassan-Morokro M, 358
Sauerwein HP, 531
Scheibel E, 107
Schleicher M, 489
Schmid P, 425
Schneider-Schaulies J, 417
Schønning K, 400
Schwartz DH, 27
Sergeant C, 392
Serpelloni G, 206
Sessler DI, 391
Shaw GM, 139
Shecterle LM, 391
Sheon AR, 577
Sherman J, 549
Shigeta S, 393
Shimada K, 41
Shinagawa H, 41
Sighinolfi L, 450
Simonoff M, 392
Singer EJ, 425
Singer M, 104
Sippy BD, 511
Skurnick J, 436
Sleeper LA, 471
Smith S, 549
Sodroski J, 506
Soro B, 358
Sorvillo F, 562
Souza E da S, 486
St Cyr JA, 391
Stahl SJ, 317
Stanley M, 381
Suprasert S, 477
Syndulko K, 425

Takamizawa A, 41
Takatsuki K, 205
Tamburrini E, 450
Tarantal AF, 129
Theetranont C, 477
Tierney M, 549
Tinari N, 450
Tossou O, 358
Tourtellotte WW, 425
Turano A, 462
Turco SJ, 496

Ullrich A, 450

Valleroy LA, 73, 82
Vallet T, 36
van der Meulen FW, 61
van der Poll T, 531
Veenhof CHN, 61
Vignoli M, 306, 408
Vila J, 36
Vilarim JA, 486
Vimal V, 540
Vlahov D, 71, 97, 206, 386
Voltz A, 186

Walach C, 48
Walker BD, 417
Walker Smith GJ, 441
Wallach D, 511
Walmsley S, 48
Wann ZF, 177
Ward JW, 374
Warrier I, 471
Waskin HA, 441
Watters JK, 381
Weeks MR, 104
Weinstein B, 73, 82
Weverling GJ, 531
Wingfield PT, 317
Wirawan DN, 569
Woody GE, 577
Wright N, 477
Wunderlich A, 489

Yamaguchi K, 205
Yao X-J, 1
Yapi A, 358
Yoang LC, 139

Zauli G, 306, 408
Zhang MJ, 317
Ziegler E, 489

Journal of Acquired Immune Deficiency Syndrome
10: 589–592 © 1995 Lippincott–Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndrome
Volume 10, 1995

Subject Index

Abidjan, HIV/AIDS epidemic in, 358
Africa
  declining CD4 counts in women of, 457
  detection of perinatally acquired HIV-1 infection in, 186
  Projet RETRO-CI data collected in, 358
  quantification of HTLV-II proviral copies in PBMCs of drug users in, 198
AIDS drug trials, differences in participation in, 562
AIDS epidemic, in Abidjan, 358
AIDS knowledge, among female sex workers, 569
AIDS risk
  ethnic differences in, 554
  in injecting drug users in methadone treatment, 90
  race/ethnicity as indicator of, 374
AIDS survival, weight loss prior to clinical infection and, 366
AIDS-defining disease, *Pneumocystis carinii* pneumonia as, 485
AIDS-related complex, CD4-immunoglobulin G in, 150
Alcohol, in AIDS risk, 554
Amerindians
  HTLV-II detection in, 205
  quantification of HTLV-II proviral copies in PBMCs of drug users in, 198
Amino acid sequence, in Vpx protein incorporation into SIV virion particles, 506
Antibody-dependent cellular cytotoxic (ADCC) effector, natural killer activity and, 115
Anti-HIV activity, ddI plus HU, 36
Anti-HIV-1 antibody IgG, detection of in whole saliva, 41
Antiretroviral therapy
  plasma viral load testing of, 139
  safety, pharmacokinetics, and response to, 150
  tolerability and pharmacokinetics of in advanced HIV, 549
Anti-Tat antibody, effect on viral replication and progression of HIV-1 disease, 408
Armed forces, HIV type-1 seroconversion trends in, 177
Autocrine loop, of HIV type-1 tat protein, 306
AZT. *See* Zidovudine

Brain, tumor necrosis factor-α in, 511
Brazil, seroprevalence of HIV-1 in pregnant women of, 486

CD4 cell count
  alternative methodologies for determining, 522
  decline in HIV-1 seropositive female sex worker *vs.* women of general population, 457
  90K antigen and, 450
  in zidovudine treatment assessment, 531
$CD4^+$ cells
  activation of, 393
  interferon-gamma synthesis of, 462
  serum and CSF levels of, 425
$CD8^+$ cells, interferon-gamma synthesis of, 462
CD16-CD56 cell populations, with natural killer cell immunodeficiency, 331
CD4-immunoglobulin G, safety, pharmacokinetics, and antiviral response of, 150
CD45RA cells, in HIV infection, 107
$CD45RO^+/CD8^+$ cells, associated with previous severe HIV infection, 107
Cell sorting, of natural killer cell subsets, 331
Cellular immune response, after mucosal immunization with recombinant *Salmonella,* 489
Central nervous system, TNF-α expression in, 511
Cerebrospinal fluid, HIV-1 RNA in, 425
Combination therapy, for HIV-1 infection, 36
Condom use, in female sex workers, 569
Conserved regions, P6 domain of Pr55gag, 1
Cryptosporidiosis, Letrazuril in treating refractory diarrhea of, 48
Cytokines
  expression of in brain of patients with AIDS, 511
  pentoxifylline inhibition of release of, 417
Cytomegalovirus infection, in clinically stable HIV infection, 324
Cytotoxic T lymphocyte
  cytokine release of HIV-specific, 417
  in immune response to HIV-1, 27
Cytotoxicity, pentoxifylline inhibition of, 417

Diagnosis
  of HIV-1 in Rwandan infants, 186
  with whole saliva, 41
Diarrhea, cryptosporidial, 48
Didanosine
  dideoxynucleosides with, 169
  sachets *vs.* chewable tablets of, 163
Didanosine-hydroxyurea therapy, anti-HIV response to, 36
Didanosine-zidovudine therapy, in HIV-seropositive males, 54
Dideoxynucleoside-induced toxic neuropathy, risk for in HIV infection, 169
Disability, in HIV infected population, 350
Disease progression
  anti-Tat antibody effect on, 408
  declining CD4 counts and, 457
  90K tumor antigen and, 450
  neutralizing antibodies and, 400
  shift from type I lymphocyte pattern in, 471
Drug paraphernalia law, 73, 82
Drug users. *See* Injecting drug users
Drug-drug interaction, zidovudine-didanosine, 54

Editorial, 71
Encephalitis, HIV-1, 425
Envelope glycoprotein, humoral response to, 13
Enzyme immunoassay
  in diagnosis of HIV-1 infection, 41
  for injecting drug users, 381
Epidemiology
  of HIV infection in injecting drug users, 381
  of HIV type-1 seroconversion among young service personnel, 177
Epitope mapping, with rgp160 vaccine therapy, 13
Ethics, of prenatal HIV testing, 341
Ethnic groups
  AIDS risk difference in, 374
  alcohol, sexual practices, and AIDS risk among, 554
  differences in participation in experimental drug trials among, 562
  quantification of HTLV-II proviral copies in PBMCs of, 198
Europe, *Pneumocystis carinii* pneumonia as AIDS-defining disease in, 485
Experimental drug trials, differences in participation in, 562

Female sex workers
  AIDS knowledge, risk behaviors, and condom use among, 569
  declining CD4 counts in, 457
Fetal growth, viral virulence and in SIV-infected macaques, 129
Flow cytometry, of T lymphocytes in patients with AIDS, 462
ß-D-Galactosidase, in detection of anti-HIV-1 antibody IgG, 41

Glucosidase inhibitors, in *N*-butyl-deoxynojirimycin tolerability and pharmacokinetics, 549
gp160 vaccine, cytotoxic T lymphocytes against, 27
gp120-LAI, T cell responses to, 489
gp120/41-specific antibody-dependent cellular cytotoxic (ADCC) effector, natural killer activity and, 115

Health status, Karnofsky Performance Status measurement of, 350
Hemophiliacs, anti-Tat antibody levels in, 408
Herpes simplex virus type 2, polyanionic compound effects on, 8
Herpesvirus infection, polyanionic compound effects on, 8
Heterosexual transmission
  PCR analysis of, 436
  in young Thai men, 477
HIV. *See* HIV-1 infection; HIV testing; HIV vaccine; Human immunodeficiency virus infection
HIV antibody, accuracy of saliva test for, 484
HIV-1 envelope, humoral responses to linear epitopes on, 13
HIV-1 infection
  in Abidjan, 358
  anti-gp160 cytotoxic T lymphocytes in, 27
  anti-HIV response to ddI plus HU therapy for, 36
  autocrine loop of tat protein of, 306
  declining CD4 counts and, 457
  diagnosis with whole saliva, 41
  effect of Tat-protein antibody on, 408
  interaction of Rev protein of with REE sequence, 317
  measles antibody response abnormalities in, 540
  neutralizing antibodies in slowly progressing, 400
  p24 antigen detection of in Rwandan infants, 186
  in pregnant women, 486
  seroconversion trends for among young service personnel, 177
  TSST-1 enhanced replication of, 393
  Vpr incorporation into, 1
  weight loss and survival in, 366
HIV-1 RNA
  in antiretroviral therapy assessment, 139
  PCR quantification of with and without neurologic abnormalities, 425
HIV-2 surveillance, in Abidjan, 358
HIV testing
  and CPR results, 381
  prenatal, 341
  of saliva, 484
HIV vaccine
  among Italian injecting drug users, 206
  with female injection drug users, 577
  injecting drug users in trial of, 386
HIV-1-induced syncytia inhibition, 496
Host defense, 90K tumor-associated antigen in, 450
Human immunodeficiency virus infection
  asymptomatic, 531
  CMV infection in clinically stable, 324
  deregulating sale and possession of syringes to prevent, 71
  epidemic in Abidjan, 358
  in heterosexual partners of HIV-infected individuals, 436
  incidence among New Haven needle exchange participants, 175
  increased $CD45RO^+/CD8^-$ cells with, 107
  Karnofsky Performance Status assessment of, 350
  lymphocyte pattern with progression of, 471
  natural killer cell immunodeficiency in, 331
  N-butyl-deoxynojirimycin tolerability and pharmacokinetics in, 549
  NK and ADCC effector function in, 115
  perinatal transmission of, 341
  progression of, 450
  risk behaviors in injecting drug users and, 90
  risk factors for dideoxynucleoside-induced toxic neuropathy in, 169
  serum selenium predicting outcome of, 392
  simulation of epidemic, 207
  spindle cell heterogeneity in, 295
  vaginal microbicides for, 8
  zidovudine and didanosine coadministration for, 54
  zygomycosis and, 441
Human Retrovirology HTLV and Related Viruses, Seventh International Conference on, 209
Human T lymphotropic virus (HTLV), conference on, 209
Human T lymphotropic virus type I (HTLV-I), neurologic diseases and, 192
Human T lymphotropic virus type II (HTLV-II)
  detection in Amerindian family, 205
  quantification of proviral copies by competitive polymerase chain reaction, 198
Humoral response, to linear epitopes of HIV-1 envelope, 13
Hydroxyurea, in HIV-1 therapy, 36
Hyperthermia, whole-body, 391

Immune complex dissociation
  HIV-1 p24 antigen assay in antiretroviral therapy assessment, 139
  p23 antigen, diagnostic utility of in Rwandan infants, 186
Immune response, after mucosal immunization, 489
Immunoblotting, for detecting antibody response to linear epitopes, 13
Informed consent, of injecting drug users in HIV vaccine trial, 386
Injecting drug users
  acquisition and use of needles and syringes by, 97
  HIV vaccine efficacy trials among, 577
  in HIV vaccine trial, 386
  interest in HIV vaccines among, 206
  90K antigen in, 450
  legal access to needles and syringes for, 73, 82
  PCR and antibody results from HIV testing of, 381
  purchasing of syringes by, 104
  quantification of HTLV-II proviral copies in PBMCs of, 198
  sale and exchange of syringes by, 104
  sale and possession of syringes among, 71
  zygomycosis and HIV infection in, 441
Insulin-like growth factor, viral virulence in SIV-infected macaques and, 129
Interferon, in murine cytomegalovirus infection, 120
Interferon-α_{2b}, low-dose, long-term, in early-stage Kaposi's sarcoma, 157
Interferon-gamma
  lymphocyte synthesis of in AIDS patients, 462
  pentoxifylline inhibition of release of, 417
Interleukins, expression of in brain of patients with AIDS, 511
Intrauterine growth, viral virulence and in SIV-infected macaques, 129

Kaposi's sarcoma
  heterogeneity of spindle cells in, 295
  low-dose, long-term interferon-α_{2b} and zidovudine in early stage of, 157
  photodynamic therapy for, 61
Karnofsky Performance Status, validity of in HIV-infected sample, 350
Kenya, declining CD4 counts in women of, 457

L-697,661 therapy, plasma viral load testing of, 139
Laser therapy, for cutaneous Kaposi's sarcoma, 61
Legislation
  on access to needles and syringes, 82
  on needle and syringe sales, 73
Leishmania lipophosphoglycan, inhibiting HIV-1-induced syncytia formation, 496
Letrazuril, for refractory cryptosporidial diarrhea, 48
Letters to Editor
  Accuracy of saliva test for HIV antibody, 484
  In Eastern Connecticut, IDUs purchase syringes from pharmacies but don't carry syringes, 104
  HTLV-II detection in an Amerindian family in Colombian southern Andean region, 205

Interest in HIV vaccines among Italian injection drug users, 206
Recent trends in *Pneumocystis carinii* pneumonia as AIDS-defining disease in nine European countries, 484
Sale and exchange of syringes, 104
Seroprevalence of HIV-1 among pregnant women in Recife, Northeastern Brazil, 486
Serum selenium predicts outcomes in HIV infection, 392
Simulation of the San Francisco HIV epidemic: AZT a possible epidemiological modulator, 207
Whole-body hyperthermia, 391
Whole-body hyperthermia (author's reply), 391
Lipophosphoglycan, inhibiting HIV-1-induced syncytia formation, 496
Long terminal repeat transactivation, by tat protein, 306
Lymphocytes
alternative methodologies for determining count of, 522
profiles with HIV disease progression, 471

Maternal health, prenatal HIV testing and, 341
Measles antibody response, abnormalities of in HIV-1 infection, 540
Methadone treatment, risk behaviors in injecting drug users entering, 90
Microbicides, for vaginal HIV and HSV-2, 8
$ß_2$-Microglobulin, in HIV progression, 450
Monkeys, intrauterine growth in SIV-infected, 129
Mucormycosis, case reviews of, 441
Mucosal immunization, gp-120-specific cell-mediated immune responses after, 489
Murine AIDS, retroviral immunodeficiency potentiating, 120
Murine cytomegalovirus (MCMV) infection, retroviral immunodeficiency potentiating, 120
Myelopathy, HTLV-I associated, 192

Natural killer cells
antibody-dependent cellular cytotoxic effector and, 115
immunodeficiency of in HIV infection, 331
in murine cytomegalovirus infection, 120
N-butyl-deoxynojirimycin, tolerability and pharmacokinetics of with advanced HIV, 549
Needle exchange programs, 104
HIV incidence in, 175
Needles
acquisition and use of by injecting drug user in Baltimore, 97
increased legal access to, 73
legal access to, 82
Needlestick injury, 82
Neopterin
90K antigen and, 450
levels of, 531
Neurologic diseases, HTLV-1-related, 192
Neuropathy, dideoxynucleoside-induced, 169
Neutralizing antibodies, in slowly progressing HIV-1 infection, 400
Nutrition, AIDS survival and, 366

Opportunist infections, in racial/ethnic groups, 374

p24 antigen
anti-Tat antibody levels and, 408
detection in Rwandan infants, 186
p24 antigenemia, in HIV progression, 450
Panama, HTLV-1 and neurologic diseases in, 192
Pediatric AIDS, p24 antigen detection of, 186
Pentoxifylline, inhibition of cytotoxicity and cytokine release by, 417
PEPSCAN, in detecting antibody response to linear epitopes, 13
Perinatal transmission, HIV infection, 341
Peripheral neuropathy, risk factors for in HIV infection, 169
Pharmacokinetics
in advanced HIV, 549
of didanosine, 163
of zidovudine and didanosine coadministration, 54
Pharmacy, needle and syringe sales of, 73
Photodynamic therapy, in AIDS-related cutaneous Kaposi's sarcoma, 61
Photofrin-Photosensitizer, in cutaneous Kaposi's sarcoma, 61
Plasma viral load testing, of antiretroviral therapy, 139
Pneumocystis carinii pneumonia, as AIDS-defining disease, 485
Police, impact of legal access to needles and syringes on, 82
Polyanionic compounds, in preventing mucocutaneous HSV-2 infection, 8
Polymerase chain reaction analysis
concordance with HIV testing antibody results, 381
of HIV-seronegative, heterosexual partners of HIV-infected individuals, 436
in quantification of HTLV-II proviral copies, 198
in quantifying HIV-1 RNA on CSF and serum, 425
Pregnancy, seroprevalence of HIV-1 in during, 486
Prenatal HIV testing, positive results of, 341
Prevention
with female injection drug users, 577
legal access to needles and syringes and, 73
Pr55gag, P6 domain of, 1
Projet RETRO-CI data, 358
Prostitutes
AIDS knowledge, risk behaviors, and condom use among, 569
in HIV transmission, 477
Proviral load, HTLV-II, 198
Psychological risk, of positive prenatal HIV test, 341

QC-PCR assay, in antiretroviral therapy assessment, 139

Race, as AIDS risk indicator, 374. *See also* Ethnic groups
REE sequence, interaction with Rev protein, 317
Retinitis, cytomegaloviral, 324
Retroviral immunodeficiency syndrome, in resistance to MCMV disease, 120
Retrovirology conference, 209
Rev protein, interaction with RRE target sequence, 317
Reverse transcriptase, in diagnosis of HIV-1 infection, 41
rgp160 vaccine therapy, humoral responses to, 13
Risk behaviors
among female sex workers, 569
in injecting drug users, 90
for young Thai men, 477
Risk factors
for dideoxynucleoside-induced toxic neuropathy with HIV infection, 169
race/ethnicity as, 374
Rwanda, detection of perinatally acquired HIV-1 infection in, 186

Saliva testing
accuracy of, 484
detection of anti-HIV-1 antibody IgG in, 41
Salmonella, recombinant, 489
Selenium, serum levels and HIV outcome, 392
Seroconversion trends, among young service personnel, 177
Serological diagnosis, in Rwandan infants, 186
Seronegative vaccine, anti-gp160 cytotoxic T lymphocyte response to, 27
Service personnel, HIV type-1 seroconversion trends among, 177
Sex workers
AIDS knowledge, risk behaviors, and condom use among, 569
declining CD4 counts in, 457
Sexual practices, AIDS risk with, 554
Sexually transmitted disease
among sex workers, 569
vaginal microbicides for, 8
Simian immunodeficiency virus (SIV)
fetal growth and viral virulence of, 129
Vpx protein incorporation into virion particles of, 506
SIVmac239, Vpx protein incorporation into, 506

Socioeconomic status, differences in participation in experimental drug trials with, 562
Southeast Asia, female sex workers in, 457, 569
Spindle cells, in Kaposi's sarcoma, 295
Substance abuse. *See* Injecting drug users
Superantigen toxic shock syndrome toxin-1, in PBMC HIV-1 replication, 393
Surrogate markers, in zidovudine treatment assessment, 531
Survival predictor, weight loss prior to AIDS as, 366
Syncytia, inhibition of by lipophosphoglycan, 496
Syringes
  acquisition and use of by injecting drug user in Baltimore, 97
  increased legal access to, 73
  legal access to, 82
  purchasing and possession of by injecting drug users, 104
  sale and exchange of, 104
  sale and possession of, 71
  tracking and testing data on, 175

T lymphocytes
  $CD4^+$ and $CD8^+$ subpopulations of, 107
  subset patterns with disease progression, 471
Tat protein
  autocrine loop of HIV type-1, 306
  effect of antibody to, 408
Thailand, risk behavior for HIV infection among young men of, 477
Toxic neuropathy, dideoxynucleoside-induced, 169
Toxic shock syndrome toxin-1, in HIV-1 replication, 393
Transmission, heterosexual, 436, 477
Tropical spastic paraparesis, relation to HTLV-1 of, 192
Tumor necrosis factor-α
  in HIV-1 replication, 393
  pentoxifylline inhibition of release of, 417
Tumor necrosis factor receptors, as surrogate HIV markers, 531
Tumor necrosis factor-α receptors, increased expression in brains of patients with AIDS, 511
90K Tumor-associated antigen, in HIV progression, 450

Vaccine
  among injection drug users, 206, 386, 496
  anti-gp160 cytotoxic T lymphocyte response to, 27
  efficacy trials for with female injection drug users, 577
  humoral responses to, 13
  immune responses after, 489
Vaccinia-gp 160-based vaccine, cytotoxic T lymphocytes against, 27
Vaginal microbicides, search for, 8
Viral fusion, 496
Viral load
  in antiretroviral therapy, 139
  PCR quantification of, 425
Viral replication, anti-Tat antibody effect on, 408
Viral virulence, effects on intrauterine growth in SIV-infected fetal rhesus macaques, 129
Virion packaging, 506
Viruria, cytomegaloviral, 324
Vpr, incorporation into HIV type 1, 1
Vpx protein, incorporation into SIV virion particles, 506
Vpx-Vpr fusion protein, 506

Wasting syndrome, survival and, 366
Weight loss, as survival predictor, 366
Women
  declining CD4 cell counts in HIV-1 seropositive, 457
  HIV disease in, 341
  injection drug using, 577
  seroprevalence of HIV-1 in during pregnancy, 486

Zalcitabine, dideoxynucleosides with, 169
Zidovudine
  as epidemiological modulator, 207
  low-dose, long-term, in early-stage Kaposi's sarcoma, 157
  plasma viral load testing of, 139
  TNF receptors as surrogate markers for assessment of, 531
Zidovudine-didanosine therapy, in HIV-seropositive males, 54
Zygomycosis, case reviews of, 441